Photoeradication of Helicobacter pylori using 5-aminolevulinic acid: Preliminary human studies

Background and Objectives Helicobacter pylori (HP) is an endemic pathogenic bacterium causing gastritits and gastroduodenal ulceration in humans and is linked to the development of gastric malignancies. These first human in vivo studies investigated the photoeradication of HP using laser and white l...

Full description

Saved in:
Bibliographic Details
Published inLasers in surgery and medicine Vol. 31; no. 1; pp. 18 - 22
Main Authors Wilder-Smith, Clive H., Wilder-Smith, Petra, Grosjean, Pierre, van den Bergh, Hubert, Woodtli, Alain, Monnier, Philippe, Dorta, Gian, Meister, Friedrich, Wagnières, Georges
Format Journal Article
LanguageEnglish
Published New York Wiley Subscription Services, Inc., A Wiley Company 01.01.2002
Wiley-Liss
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Background and Objectives Helicobacter pylori (HP) is an endemic pathogenic bacterium causing gastritits and gastroduodenal ulceration in humans and is linked to the development of gastric malignancies. These first human in vivo studies investigated the photoeradication of HP using laser and white light. Study Design/Materials and Methods In 13 HP‐positive volunteers, a zone of gastric antrum was irradiated with laser (410 nm, 50 J/cm2) or endoscopic white light (10 J/cm2) 45 minutes after oral 5‐aminolevulinic acid (5‐ALA) 20 mg/kg. HP‐eradication was assessed by biopsy urease test and HP‐culture from irradiated and control zones 5 minutes, 4 and 48 hours post‐irradiation. Results A maximum eradication effect was achieved at 4 hours post‐irradiation when 85% of biopsies in the monochromatic and 66% in the white light exposed zones, and 58 and 33% in the respective control zones were HP‐negative. Conclusions HP numbers were greatly reduced following exposure to 5‐ALA and either laser or white light in vivo. Photoeradication appears feasible, but further light dosimetry and the development of convenient application methods is required. Lasers Surg. Med. 31:18–22, 2002. © 2002 Wiley‐Liss, Inc.
Bibliography:istex:F7C218D0AB3C52007ACDA5F3172DE24E62754671
ark:/67375/WNG-C0JB290X-P
ArticleID:LSM10066
Takeda AG (Switzerland)
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ISSN:0196-8092
1096-9101
DOI:10.1002/lsm.10066